This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burton, R. L. Articles by Nahm, M. H. Search for Related Content PubMed PubMed Citation Articles by Burton, R. L. Articles by Nahm, M. H.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, September 2006, p. 1004-1009, Vol. 13, No. 9
1071-412X/06/$08.00+0     doi:10.1128/CVI.00112-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Development and Validation of a Fourfold Multiplexed Opsonization Assay (MOPA4) for Pneumococcal Antibodies

Departments of Pathology,¹ Microbiology, University of Alabama at Birmingham, Birmingham, Alabama²

Received 23 March 2006/ Returned for modification 31 May 2006/ Accepted 12 July 2006

Opsonophagocytic killing assays (OPAs) are essential for developing and improving pneumococcal vaccines. There is a need for a high-throughput, reliable, standardized, and fully characterized OPA for pneumococcal antibodies. To meet the need, we have developed and characterized a fourfold multiplexed OPA (MOPA4) against 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) of pneumococci. Thirteen target bacteria were made resistant to only one of the following antibiotics: optochin, streptomycin, spectinomycin, and trimethoprim. Following optimization of assay conditions, accuracy of MOPA4 was determined by testing 30 sera from old adults in the MOPA4 and the single-serotype assays. The opsonization titers obtained with both assays agreed well (r² > 0.95). Although 22 (out of 390; 6%) results differed more than twofold, the differences were not reproducible. The assay was specific: preabsorbing test sera with homologous polysaccharide (PS) completely abrogated opsonic activity, but a pool of unrelated PS (5 µg/ml of each) had no effect. Intra- and interassay coefficients of variation were 10 and 22%, respectively. MOPA4 results were unaffected by having different target pneumococcal serotypes in each assay group. Also, HL60 cell-to-bacteria ratios could be varied twofold without affecting the results. We conclude that MOPA4 is sensitive, accurate, specific, precise, and robust enough for large-scale clinical studies. Furthermore, MOPA4 should allow evaluation of multivalent pneumococcal vaccines with the limited volume of serum typically available from young children.

This article has been cited by other articles:

• Schenkein, J. G., Nahm, M. H., Dransfield, M. T. (2008). Pneumococcal Vaccination for Patients With COPD: Current Practice and Future Directions. Chest 133: 767-774 [Abstract] [Full Text]